The Out-of-pocket Expenses of People With Tinnitus in Europe
- PMID: 38797674
- PMCID: PMC11464849
- DOI: 10.2188/jea.JE20230358
The Out-of-pocket Expenses of People With Tinnitus in Europe
Abstract
Background: Despite the high frequency of tinnitus and its impact on wellbeing, little is known about its economic burden, and, to our knowledge, no data are available on out-of-pocket (OOP) expenses.
Methods: In 2022, a survey was conducted on OOP costs of tinnitus. We enrolled 679 participants with slight, moderate, and severe tinnitus in Italy, United Kingdom, Netherlands, Germany, and Spain. We estimated annual OOP expenses for tinnitus-related healthcare visits, treatments, medications, and alternative medicine practices. Prevalence of tinnitus in the general population, obtained from a representative survey we conducted in Europe in 2017-2018, was used to generalize costs for people with any tinnitus at the national level.
Results: OOP expenses were 368€ (95% confidence intervals [CI], 78€-690€), 728€ (95% CI, 316€-1,288€), and 1,492€ (95% CI, 760€-2,688€) for slight, moderate, and severe tinnitus, respectively, with annual expenditure of 565€ for people with any tinnitus: 209€ for healthcare visits; 93€ for treatments; 16€ for drugs; 64€ for hearing supporting systems; and 183€ for acupuncture, homeopathy, and osteopathy. Individuals with slight, moderate, and severe tinnitus expressed a willingness to invest 1.6, 4.3, and 7.0 times their monthly income, respectively, to achieve complete relief from tinnitus.
Conclusion: This study offers for the first time insights into the OOP expenses incurred by individuals with tinnitus. OOP expenses exhibited substantial variations based on severity status, accounting for more than 17 billion € in the countries considered. In terms of financial burden, these findings align tinnitus to the recognized leading disabilities, including back pain and migraine.
Keywords: economic burden; epidemiology; out of pocket costs; patients’ perspective; tinnitus.
Conflict of interest statement
Conflicts of interest: CMJ, KK, IT, ABR, RC, CRC, JALE, DK, BL, AL, BM, MS, SS, JPS, WS and SGallus received funding within the UNITI project. The same authors obtained support for attending meetings and travel from the same UNITI project. RC was supported by KU Leuven. JALE also received support for attending meetings and travel from the University of Sydney. BL received grants from the German Research Foundation, the German Bundesministerium für Bildung und Forschung, the European Union, the Bavarian-Czech University Association, and the Bavarian State. BL also received consulting fees and/or payments from Schwabe, Neuromod, Sea Pharma, Rovi. BL received payment for expert testimony from Bavarian State. BL holds an unpaid leadership role at Tinnitus Research Initiative and German Society for Brain Stimulation in Psychiatry. BL has stock in Sea Pharma and received equipment from Neurocare, Daymed. BM received additional support for attending meetings and travel from Charité – Universitätsmedizin Berlin. JPS received grants from the University of Twente and the University of Regensburg. WS declared to be stakeholder of Lenox uG and serves as a consultant for Pansatori GmbH, and Pohl-Boskamp GmbH & Co. KG. WS is speaker for Schwabe Pharma AG, and Medical Tribune, and holds the patent US20120046713A1.
